Rx Medicare

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, announced the Company has initiated a third Phase 2a study of KAI-1678, a first-in-class, isozyme-selective, small peptide inhibitor of the epsilon protein kinase C pathway (epsilon PKC). The study has begun enrollment of patients for the treatment of chronic neuropathic pain associated with spinal cord injury (SCI).

Read More…

Related Posts

• KAI Pharmaceuticals Expands KAI-1678 Development Program, Initiating A Phase 2a Study For Neuropathic Pain
• QRxPharma Initiates Pivotal Phase 3 Study Of MoxDuo(TM)IR For Moderate To Severe Acute Pain
• Transdel Pharmaceuticals Announces Positive Phase 3 Study Results For Lead Topical Pain Drug Ketotransdel(R)
• Valeant Pharmaceuticals Announces Preliminary Results From Its Phase IIa Retigabine Study For The Treatment Of Postherpetic Neuralgia (PHN)
• QRxPharma Initiates Comparative Phase 2 Proof-of-Concept Study For MoxDuo(TM) IV Pain Therapy
• Cerimon Pharmaceuticals Initiates Phase III Clinical Studies To Evaluate Its Topical Diclofenac Sodium Patch For Mild-to-Moderate Pain
• Alkermes Announces Positive Results For Phase 1 Study Of New Drug Candidate For Treatment Of Opioid-Induced Constipation
• Study examines course and treatment of unexplained chest pain
• Third Party Reexamination Of Javelin Pharmaceuticals’ Phase III Trial Data For Ereska Yields Statistically Significant Primary Endpoint
• QRxPharma Initiates Second Pivotal Phase 3 Study Of MoxDuo(TM)IR Dual-Opioid(TM) For NDA Submission
• China Aoxing Pharmaceutical Company Announces Successful Completion Of Phase II Clinical Study Of Novel Menstrual Pain Drug
• Barriers To Pain Treatment In Children With Sickle Cell Disease Revealed By New Study
• U-M Receives $1.8 Million To Develop Therapy For Neuropathic Pain
• Alkermes Announces Initiation Of Phase 1 Clinical Study Of ALKS 37 For The Treatment Of Opioid-Induced Constipation
• Drug Used For Neuropathic Pain Relieves Discomfort From Abdominal Adhesions: Henry Ford Study

Tags: 1678, develop, initiates, neuropathic, pain, pharmaceuticals, phase, program, study, third, treatment

This entry was posted on Tuesday, April 14th, 2009 at 7:04 pm and is filed under Analgesics Pain Migraine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.